Mishle Shelomoh ben David Proverbia Salomonis : iam denuo iuxta Hebraicam ueritatem translata, & Annotationibus grammaticis illustrata, autore Sebastiano Munstero

(Conradus Pellicanus [Vorr.])

Der Reisebericht des David Reubeni : ein Beitrag zur Geschichte des XVI. Jahrhunderts

Leipzig, Univ., Diss., 1892

David's violin : opera

by Lateiner & Mogulesco. Arr. by H. A. Russotto

David Montezinos : de stichter der "Livraria D. Montezinos" ; (1 Thebet 5589-5674)

door J. S. da Silva Rosa

Rede des Abgeordneten Johann Jacoby : gehalten vor einer Wähler-Versammlung am 12. September 1848

Boberach: Der (neben Geheimrat Jonas) im viertgrößten Berliner Wahlbezirk gewählte Abgeordnete wird sich, obwohl selber Anhänger der Republik, der Mehrheitsentscheidung für die konstitutionelle Monarchie beugen, in der die Volksvertretung entscheidet, König und Minister nur raten und warnen dürfen. Die beiden letzten preußischen Ministerien haben das Heer als Hochburg reaktionären Junkertums nicht genug kontrolliert

Erzherzog Johann von Oesterreich der Deutsche Reichsverweser, und sein bisheriges Verhältniß zum deutschen Volke : [biographische Skizze] ; nach glaubwürdigen Quellen mitgetheilt

Welsch (Projektbearbeiter): Kurze Darstellung der Wahl Erzherzog Johanns zum Reichsverweser (29. Juni 1848) sowie seines bisherigen Lebenslaufes

Deutschlands Wiedergeburt! Gedicht: Seiner Kaiserlichen Hoheit, dem Erzherzoge Johann von Oesterreich, erwähltem ersten Deutschen Reichsverweser, am Tage Seines hochgefeierten Einzuges zu Frankfurt am Main, den 11. Juli 1848, in tiefster Ehrfurcht gewidmet

Welsch (Projektbearbeiter): Gedicht zu Ehren des am 29, Juni 1848 von der Nationalversammlung zum unverantwortlichen Reichsverweser gewählten Erzherzogs Johann

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

BACKGROUND Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. METHODS Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544). FINDINGS 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60-71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184). Median follow-up was 43 months (IQR 30-60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79-1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66-0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69-0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3-5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. INTERPRETATION Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. FUNDING Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research.

Das deutsche Volk in Frankfurt hat gesiegt! Erzherzog Johann ist in Gefahr! Nachrichten über Nachrichten durchlaufen die Residenz Wien über die blutigen Ereignisse in Frankfurt ...

Welsch (Projektbearbeiter): Nachricht über den Septemberaufstand in Frankfurt/Main. Meldung über den Tod der Abgeordneten Auerswald und Lichnowsky (zutreffend) und des Abgeordneten Heckscher (nicht zutreffend). Äußerung von Sorge um die Sicherheit von Erzherzog Johann bei grundsätzlich positiver Haltung zu den Geschehnissen.

Vivat Erzherzog Johann, der wackere Tiroler-Hanns: Welch' Glück uns wartet, und was wir hoffen, Liegt in diesen Worten frei uns offen! Welchen Vaterlandsfreund erfreuet nicht dieser Name ...

Welsch (Projektbearbeiter): Willkommensgruß an Erzherzog Johann samt kurzer biographischer Skizze anläßlich seines Eintreffens in Wien

Tagsbefehl für die Nationalgarde. Am 28. Juni 1848: Se. kaiserliche Hoheit der Erzherzog Johann äußerten sich so günstig über die Vortrefflichkeit der Garde ...

Welsch (Projektbearbeiter): Anton Pannasch, Oberkommandant der Wiener Nationalgarde gibt mit Genugtuung das Lob Erzherzog Johanns über den Ausbildungsstand der Garde bekannt